Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis

References

• AscheCVBrixnerDIConoscentiCSAssessment of physician prescribing for primary care patients with chronic obstructive pulmonary disease (COPD) in a national electronic medical record (EMR) research databaseChest20061304175s [abstract]
   Web of Science ®Google Scholar
• BourbeauJSebaldtRJDayAPractice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE studyCan Respir J2008151131918292848
   PubMed Web of Science ®Google Scholar
• de Miguel-DíezJCarrasco-GarridoPRejas-GutierrezJI nappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health statusLung2011189319920621499887
   PubMed Web of Science ®Google Scholar
• CazzolaMSegretiABettoncelliGChange in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008Prim Care Respir J201120329129821509419
   PubMedGoogle Scholar
• MehuysEBousseryKAdriaensECOPD management in primary care: an observational, community pharmacy-based studyAnn Pharmacother201044225726620103611
   PubMed Web of Science ®Google Scholar
• SmithCJGribbinJChallenKBHubbardRBThe impact of the 2004 NICE guideline and 2003 General Medical Services contract on COPD in primary care in the UKQJM2008101214515318180254
   PubMed Web of Science ®Google Scholar
• global strategy for diagnosis, management and prevention of chronic obstructive pulmonary disease [homepage on the Internet]Global Initiative for Chronic Obstructive Lung Disease (GOLD) [updated Dec 2011] Available from: http://www.goldcopd.org/Accessed August 20, 2012
   Google Scholar
• SinghSLokeYKAn overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2010518919520714372
   PubMedGoogle Scholar
• PatelARHurstJRExtrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the artExpert Rev Respir Med20115564766221955235
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• KardosPWenckerMGlaabTVogelmeierCImpact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2007175214414917053207
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• ErnstPGonzalezAVBrassardPSuissaSInhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumoniaAm J Respir Crit Care Med2007176216216617400730
   PubMed Web of Science ®Google Scholar
• CG101 Chronic obstructive pulmonary disease (update): full guideline [webpage on the Internet]National Institute for Health and Clinical Excellence [updated May 30, 2012] Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/EnglishAccessed August 20, 2012
   Google Scholar
• QaseemAWiltTJWeinbergerSEDiagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory SocietyAnn Intern Med2011155317919121810710
   PubMed Web of Science ®Google Scholar
• ColiceGLPragmatic research and outcomes in asthma and COPDPragmatic Obs Res201231125
   Google Scholar
• CrimCCalverleyPMAndersonJAPneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study resultsEur Respir J200934364164719443528
   PubMed Web of Science ®Google Scholar
• WalshLJWongCAOborneJAdverse effects of oral corticosteroids in relation to dose in patients with lung diseaseThorax200156427928411254818
   PubMed Web of Science ®Google Scholar
• Inhaled steroids approximate dose conversions for adults [webpage on the Internet]Greater Rochester Independent Practice Association (GRIPA)2005 Available from: http://gripa.org/Documents/Pharmacy-tidbits/Steroid-Inhaler-Conversion-Chart-12-05-Pharmacy-Tidbit.pdfAccessed February 1, 2012
   Google Scholar
• JooMJAuDHFitzgibbonMLLeeTAInhaled corticosteroids and risk of pneumonia in newly diagnosed COPDRespir Med2010104224625219879745
   PubMed Web of Science ®Google Scholar
• MinasMHatzoglouCKaretsiECOPD prevalence and the differences between newly and previously diagnosed COPD patients in a spirometry programPrim Care Respir J201019436337020532466
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC)Chronic obstructive pulmonary disease and associated health-care resource use – North Carolina, 2007 and 2009MMWR Morb Mortal Wkly Rep201261814314622377845
   PubMedGoogle Scholar
• SpencerSKarnerCCatesCJEvansDJInhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201112CD00703322161409
   PubMedGoogle Scholar
• YangIAClarkeMSSimEHFongKMInhaled corticosteroids for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127CD00299122786484
   PubMed Web of Science ®Google Scholar
• SinghSAminAVLokeYKLong-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysisArch Intern Med2009169321922919204211
   PubMed Web of Science ®Google Scholar
• JonesPWWillitsLRBurgePSCalverleyPMInhaled Steroids in Obstructive Lung Disease in Europe study investigatorsDisease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbationsEur Respir J2003211687312570111
   PubMed Web of Science ®Google Scholar
• CalverleyPPauwelsRVestboJCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet2003361935644945612583942
   PubMed Web of Science ®Google Scholar
  Lancet200336193691660
   Google Scholar
• YawnBKleerupEZhangJKianifardFWilliamsJInhaled corticosteroid use and GOLD severity stage among patients with chronic obstructive pulmonary disease in different regionsAm J Respir Crit Care Med2012185A2944 [abstract]
   Web of Science ®Google Scholar
• ChenSPlauschinatCAWuNFraserKBoulangerLEconomic impact of using inhaled corticosteroids without prior exacerbation among elderly patients with chronic obstructive pulmonary disorderJ Med Econ201114445846221651427
   PubMedGoogle Scholar
• PapiABellettatoCMBraccioniFInfections and airway inflammation in chronic obstructive pulmonary disease severe exacerbationsAm J Respir Crit Care Med2006173101114112116484677
   PubMed Web of Science ®Google Scholar
• SeemungalTHarper-OwenRBhowmikARespiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200116491618162311719299
   PubMed Web of Science ®Google Scholar
• MyintPKLoweDStoneRABuckinghamRJRobertsCMUK National COPD Resources and Outcomes Project 2008: patients with chronic obstructive pulmonary disease exacerbations who present with radiological pneumonia have worse outcome compared to those with non-pneumonic chronic obstructive pulmonary disease exacerbationsRespiration201182432032721597277
   PubMed Web of Science ®Google Scholar
• CharlsonMSzatrowskiTPPetersonJGoldJValidation of a combined comorbidity indexJ Clin Epi19944712461261
   Web of Science ®Google Scholar
• FinkelsteinJChaEScharfSMChronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidityInt J Chron Obstruct Pulmon Dis2009433734919802349
   PubMedGoogle Scholar
• DaiSWalshPWielgoszAGurevichYBancejCMorrisonHComorbidities and mortality associated with hospitalized heart failure in CanadaCan J Cardiol2012281747921885240
   PubMed Web of Science ®Google Scholar
• ManninoDMThornDSwensenAHolguinFPrevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPDEur Respir J200832496296918579551
   PubMed Web of Science ®Google Scholar
• RanaJSMittlemanMASheikhJChronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in womenDiabetes Care200427102478248415451919
   PubMed Web of Science ®Google Scholar
• CalverleyPMStockleyRASeemungalTAReported pneumonia in patients with COPD: findings from the INSPIRE studyChest2011139350551220576732
   PubMed Web of Science ®Google Scholar
• HoggJCChuFSTanWCSurvival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathologyAm J Respir Crit Care Med2007176545445917556723
   PubMed Web of Science ®Google Scholar
• HoggJCChuFUtokaparchSThe nature of small-airway obstruction in chronic obstructive pulmonary diseaseN Engl J Med2004350262645265315215480
   PubMed Web of Science ®Google Scholar
• PattersonCMMorrisonRLD’SouzaATengXSHappelKIInhaled fluticasone propionate impairs pulmonary clearance of Klebsiella pneumoniae in miceRespir Res20121314022651370
   PubMed Web of Science ®Google Scholar
• HalpinDMGrayJEdwardsSJMoraisJSinghDBudesonide/formoterol vs salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trialsInt J Clin Pract201165776477421676119
   PubMed Web of Science ®Google Scholar
• SinganayagamAChalmersJDAkramARHillATImpact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumoniaEur Respir J2011381364121429980
   PubMed Web of Science ®Google Scholar
• ChenDRestrepoMIFineMJObservational study of inhaled corticosteroids on outcomes for COPD patients with pneumoniaAm J Respir Crit Care Med2011184331231621512168
   PubMed Web of Science ®Google Scholar
• RestrepoMIMortensenEMAnzuetoAAre COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying?Eur Respir J20113811321719494
   PubMed Web of Science ®Google Scholar